Girolamo Caló

发表

Spinal antinociceptive effects of the novel NOP receptor agonist PWT2‐nociceptin/orphanin FQ in mice and monkeys

C. Ruzza, R. Guerrini, A. Rizzi, 2015, British journal of pharmacology.

Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor

D. Lambert, G. Calo’, R. Guerrini, 2018, British journal of pharmacology.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111

M. Morari, G. Calo’, M. Budri, 2013, British journal of pharmacology.

L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors.

M. Morari, G. Calo’, L. Beani, 1999, The Journal of pharmacology and experimental therapeutics.

Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice

S. Salvadori, C. Ruzza, G. Calo’, 2008, British journal of pharmacology.

Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic

D. Lambert, G. Calo’, David G. Lambert, 2018, British journal of anaesthesia.

Activities of mixed NOP and μ‐opioid receptor ligands

G. Calo’, S. Husbands, J. Lewis, 2008, British journal of pharmacology.

In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP‐505

S. Salvadori, C. Ghelardini, D. Lambert, 2018, British journal of pharmacology.

A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials

R. Mechelli, M. Salvetti, G. Calo’, 2017, Scientific Reports.

Circadian variation in attempted suicide by deliberate self poisoning

G. Calo’, R. Manfredini, M. Gallerani, 1994, BMJ.